This work is licensed under a Creative Commons Attribution 4.0 International License.
LTV-X13
General Information
DRACP ID DRACP01941
Peptide Name LTV-X13
Sequence LTVSPWYGCGMPFSTGKRIMLGE
Sequence Length 23
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Active ACP
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| OPM-2 | Plasma cell myeloma; Multiple myeloma | Carcinoma | 0%Killing=50 µM | CellTox cytotoxicity assay | 30 min | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity CHO-K1: 0%Killing=50 µM; HFF: 0%Killing=50 µM; WI-38: 0%Killing=50 µM
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C114H176N28O31S3
Absent amino acids ADHNQ
Common amino acids G
Mass 292358
Pl 8.52
Basic residues 2
Acidic residues 1
Hydrophobic residues 6
Net charge 1
Boman Index -551
Hydrophobicity 15.22
Aliphatic Index 63.48
Half Life
Mammalian: 30 hour
Yeast: >20 hour
E.coli: >10 hour
Extinction Coefficient cystines 6990
Absorbance 280nm 317.73
Polar residues 10
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 26734838
Title Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy
Year 2016
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
External Code
DBAASP ID DBAASPS_12683
This work is licensed under a Creative Commons Attribution 4.0 International License.